The Research Group on Diabetes and Chronic Illnesses

Victoria de Durango, Mexico

The Research Group on Diabetes and Chronic Illnesses

Victoria de Durango, Mexico
SEARCH FILTERS
Time filter
Source Type

Guerrero-Romero F.,Mexican Social Security Institute | Guerrero-Romero F.,The Research Group on Diabetes and Chronic Illnesses | Rodriguez-Moran M.,Mexican Social Security Institute | Rodriguez-Moran M.,The Research Group on Diabetes and Chronic Illnesses
European Journal of Clinical Investigation | Year: 2011

Background: Given that role of magnesium in insulin secretion is uncertain, our objective was to determine whether oral supplementation with magnesium chloride (MgCl 2) improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia. Materials and methods Eligible individuals were non-diabetic, normo-tensive men and non-diabetic, normo-tensive, non-pregnant women with serum magnesium levels ≤0·70mM/L; they were enrolled in a randomized double-blind clinical trial to receive either 50mL of 5% MgCl 2 solution or 50mL of inactive solution daily for 3months. The primary trial end point was a change in the AUC of the hyperbolic model of beta-cell function (HMbCF) derived from the fasting state. Individuals, caregivers and personnel who assessed the outcomes were all blinded to the group assignments. Results A total of 54 and 52 individuals were assigned to the MgCl 2 and placebo groups, respectively; five individuals in the MgCl 2 group and four in the placebo group dropped out. There were no serious adverse events or side effects because of MgCl 2 or placebo. At the beginning of the study, the AUC of the HMbCF was similar in both groups (AUC=7·591 and 7·895cm 2); at the end of follow-up, the curve of the MgCl 2 group showed a hyperbolic distribution (AUC=18·855cm 2), whereas in the placebo group, there were no changes (AUC=7·631cm 2). Conclusions: MgCl 2 2·5g daily improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia. © 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.


Rodriguez-Moran M.,Mexican Social Security Institute | Rodriguez-Moran M.,The Research Group on Diabetes and Chronic Illnesses | Guerrero-Romero F.,Mexican Social Security Institute | Guerrero-Romero F.,The Research Group on Diabetes and Chronic Illnesses
Diabetes/Metabolism Research and Reviews | Year: 2011

Background: Magnesium modulates insulin-mediated glucose uptake but data regarding its role in insulin secretion are scarce; therefore, in this study we determined whether decreased serum magnesium levels are associated with the impairment of insulin secretion in non-diabetic individuals. Methods: A total of 182 apparently healthy subjects, men and non-pregnant women, 18-65 years of age, were enrolled in a population-based cross-sectional study and allocated to groups with hypomagnesaemia and normomagnesaemia. The groups in the study were subsequently stratified according to glucose status: normal glucose tolerance, impaired fasting glucose, and impaired glucose tolerance. Insulin secretion was evaluated by the first and second phases of insulin secretion. Results: The Spearman coefficient between serum magnesium and the first and second phases of insulin secretion showed a significant positive correlation in the overall (r = 0.265, p < 0.0005; r = 0.541, p < 0.0005), normal glucose tolerance (r = 0.369, p = 0.001; r = 0.618, p < 0.0005), impaired fasting glucose (r = 0.320, p = 0.02; r = 0.449, p = 0.001), and impaired glucose tolerance (r = 0.129, p = 0.37; r = 0.522, p < 0.0005) groups. The multivariate linear regression analysis showed a significant association between serum magnesium levels and the first and second phases of insulin secretion: for the entire groups [B = 75.2; 95% confidence interval (CI) 27.6-122.7; B = 25.4; 95% CI 16.4-34.3], normal glucose tolerance (B = 129.6, 95% CI 38.1-221.1; B = 40.3, 95% CI 23.7-56.8), impaired fasting glucose (B = 75.2, 95% CI 27.6-122.7; B = 15.1, 95% CI 4.2-30.2), and impaired glucose tolerance (B = 57.4, 95% CI 23.5-138.3; B = 25.4, 95% CI 16.4-34.3) groups. Conclusions: Our results show that hypomagnesaemia is associated with the decrease of the first and second phases of insulin secretion in non-diabetic subjects with hypomagnesaemia. © 2011 John Wiley & Sons, Ltd.

Loading The Research Group on Diabetes and Chronic Illnesses collaborators
Loading The Research Group on Diabetes and Chronic Illnesses collaborators